IceCure Medical Ltd.
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 4.5
- Dividend yield
- –
About IceCure Medical
Surgical & Medical Instruments & Apparatus, SIC 3841
IceCure Medical Ltd. is an Israeli medical device company that researches, develops, and commercializes liquid-nitrogen-based cryoablation systems to destroy benign and malignant tumors through freezing. Its proprietary technology provides a minimally invasive alternative to surgery for tumors in the breast, lungs, kidneys, and bones. The company's lead commercial product is the ProSense system alongside its single-use disposable CryoProbes, while its pipeline includes next-generation systems such as the single-probe XSense and multi-probe MSense platforms. IceCure primarily markets its cryoablation products to healthcare providers, physicians, and hospitals treating low-risk breast cancer and other tumor indications.
The company's cryoablation systems hold regulatory approvals for various clinical indications in 27 countries, including the United States, several European nations, China, India, and Brazil. IceCure maintains its corporate headquarters and principal executive offices in Caesarea, Israel, and operates wholly owned subsidiaries in the United States and Hong Kong.
Summary of the business section of IceCure Medical's latest annual report, written by StockData.
Company profile
Company
- Legal name
- IceCure Medical Ltd.
- Founded
- 2006
- Headquarters
- Caesarea, Israel
- Address
- 7 Ha'Eshel St., Pob 3163 38900
- Phone
- 972-4-6230333
- Website
- icecure-medical.com
- Employees
- 67, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- L3
- Fiscal year ends
- December 31
- Auditor
- Brightman Almagor Zohar & Co., Tel Aviv, Israel
Stock & identifiers
- Ticker
- ICCM
- Exchange
- Nasdaq
- IPO date
- Dec 10, 2021
- Shares outstanding
- 73M, Dec 31, 2025
- Filer category
- Non-accelerated filer<br>Emerging growth company
- Stock splits
- 1-for-30 reverse, Jun 4, 2026
- SEC CIK
- 1584371
- CUSIP
- M53071136
- ISIN
- USM530711367
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Eyal Shamir | Chief Executive Officer, Director | 791,381 |
| Meir Peleg | Chief Financial Officer | 194,816 |
| Shay Levav | Chief Operating Officer | 146,303 |
| Shad Good | VP, Sales for North America | 136,698 |
| Merav Nir Dotan | VP, Human Resources | 76,168 |
| Tlalit Bussi Tel-Tzure | VP, BD & Global Marketing | 106,518 |
| Naum Muchnik | VP, R&D & Engineering | 118,621 |
| Ronen Tsimerman | Chief Financial Officer | 177,949 |
| David Salton | Director | – |
| Vincent Chun Hung Chan | Director | – |
| Sharon Levita | Director | – |
| Yonatan Malca | Director | – |
| Ron Mayron | Director | 296,631 |
| Yang Huang | Director | 111,468 |
Employees
Headcount reported in annual reports
“we had 67 full-time employees and two part time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Dec 10, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Aug 23, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |